BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics

BeiGene has paid Zymeworks $40 million for the Asian rights to HER2-targeted bispecific antibodies ZW25 and ZW49. The agreement gives Zymeworks upfront cash, a potential ongoing income stream and a global development partner.